Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News SCYNEXIS Inc SCYX

Healthcare
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens,... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SCYX)

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 6, 2024

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire October 10, 2024

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

GlobeNewswire October 3, 2024

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire August 27, 2024

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2024

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

GlobeNewswire July 23, 2024

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 8, 2024

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

GlobeNewswire April 30, 2024

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

GlobeNewswire April 9, 2024
View More News ››

Opinion & Analysis (NDAQ:SCYX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SCYX)

RE:RE:wtf?

They sold the drug, not the company. Too bad, I wish they had sold the entire company.  I guess this useless management team gets...
JonathanJSmith - March 31, 2023

RE:wtf?

Great timing Mr. Smith...... Care to stick your other foot in your mouth?? Don't quit ur day job !
Iseneschal - March 30, 2023

wtf?

What happened to these guys? What a disgrace. Fire the entire management team and start anew. Sell this company for what can be salvaged...
JonathanJSmith - March 16, 2023

Can we expect additional Rx's to the fold this winter?

It's been a while and I've had some time to digest several variables; here are some of my findings: These guys are still trading...
JonathanJSmith - August 2, 2022

RE:RE:RE:RE:BREXAFEMME - published User side effects

I'm disgusted too. What does $45MM get them, another quarter's worth of financing - maybe two? One would think that they'd...
JonathanJSmith - April 26, 2022

RE:RE:RE:BREXAFEMME - published User side effects

I was going to sell at a loss, but decided to lower my average cost due to the discount. They will have $150M cash less Q1 spend...
dmacd - April 22, 2022
View more Bullboard ››

Indiva Ltd

Indiva Ltd

Indiva Limited, through its indirect wholly owned subsidiary, Indiva Inc., is a Canada-based producer of cannabis servicing ...
View More »